DBV Technologies Financial Results
DBV Technologies reported Q3 2026 financial results, highlighting the submission of its Biologics License Application (BLA) to the FDA for the Viaskin Peanut Patch in children aged 4-7 years. The company reported a cash position of $165.7 million, which is expected to fund operations into the third quarter of 2027 as it prepares for potential commercial launch.
- Term
- Q3 2026
“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now submitted for children aged 4 through 7 years, and our planned BLA in toddlers aged 1 through 3 years, we are concentrating our efforts on the areas that will advance the company most meaningfully.”
Daniel Tassé, Chief Executive Officer of DBV Technologies
“We are grateful for the productive, ongoing dialogue with the FDA about both BLAs. As the regulatory dialogue progresses, we have every function across the company aligned on supporting a complete and efficient review of both dossiers, advancing manufacturing readiness alongside our contract manufacturing partner, and preparing to execute our launch plans with discipline.”
Daniel Tassé, Chief Executive Officer of DBV Technologies